文献速递肝病

代谢功能障碍相关脂肪性肝病临床结局与肝失代偿的自然史

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-04-03

这项纵向回顾性分析纳入2016例代谢功能障碍相关脂肪性肝病患者,中位随访3.2年。220例(11%)发生肝失代偿,腹水为最常见首发事件(153例,69.5%),从首次肝失代偿至死亡或肝移植的中位生存时间为2.0年。

要点

  • MASLD患者中11%发生肝失代偿,腹水为最常见首发事件(69.5%)。
  • 首次肝失代偿至死亡或移植的中位生存时间为2.0年。
  • 首次至第二次失代偿中位时间0.7年,第二次至第三次1.3年。

核心结论

  • MASLD患者最常见的首发肝脏相关事件是腹水,从首次肝失代偿至死亡或肝移植的中位生存时间为2年。

研究设计与样本

  • 纵向回顾性分析,纳入2016例特征明确的MASLD患者队列,随访肝失代偿和死亡。

主要发现

  • 2016例中220例(11%)在中位随访3.2年内发生至少一次肝失代偿。
  • 首次肝脏相关事件中腹水153例(69.5%)、肝性脑病55例(25%)、静脉曲张出血30例(13.6%)。
  • 220例中18例(8.1%)以不止一个肝脏相关事件作为首次肝失代偿。
  • 发生首次事件的患者中87例(39.5%)发生第二次事件:肝性脑病44例(50.5%)、腹水31例(35.6%)、静脉曲张出血12例(13.7%)。
  • 220例中18例(8.1%)发生第三次事件:肝性脑病10例(55.5%)、静脉曲张出血6例(33.3%)、腹水2例(11.1%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The natural progression of hepatic decompensation in metabolic dysfunction-associated steatotic liver disease (MASLD) is not well-characterised. We aimed to describe it by conducting a retrospective analysis. METHODS: This longitudinal, retrospective analysis of well-characterised MASLD cohorts followed for hepatic decompensation and death. The sequence of liver-related events was evaluated, and the median time between hepatic decompensation episodes and death versus. transplantation was measured. RESULTS: Of the 2016 patients identified, 220 (11%) developed at least one episode of hepatic decompensation during a median follow-up of 3.2 years. Ascites was the most common first liver-related event [153 (69.5%)], followed by hepatic encephalopathy (HE) [55 (25%)] and variceal haemorrhage (VH) [30 (13.6%)]. Eighteen out of the 220 (8.1%) patients had more than one liver-related event as their first hepatic decompensation. Among the patients who had the first episode, 87 (39.5%) had a second episode [44 (50.5%) HE, 31 (35.6%) ascites, and 12 (13.7%) VH]. Eighteen out of 220 (8.1%) had a third episode [10 (55.5%) HE, 6 (33.3%) VH, and 2 (11.1%) ascites]. Seventy-three out of 220 (33.1%) died, and 31 (14%) received liver transplantation. The median time from the first episode to the second was 0.7 years and 1.3 years from the second episode to the third. The median survival time from the first episode to death or transplantation was 2.0 years. CONCLUSION: The most common first liver-related event in MASLD patients is ascites. The median survival from the first hepatic decompensation to either death or transplantation is 2 years.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Noureddin N, Huang DQ, Bettencourt R, et al. Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024. PMID: 38571305. doi:10.1111/apt.17981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。